Corcept Bears Pressed Into a 30% Slide

CORT has dropped 30% over the past month to $81.93, and short sellers have been adding exposure through the decline. Short interest now covers 8.1% of the free float, up roughly 1.6% over the past week, with the position building gradually since early October after a brief flush lower in short shares through mid-month. Borrowing costs have risen 27% week-on-week to 0.38%, a move that is directionally notable even if the absolute rate remains low. Availability is ample at 1,310%, meaning the lending pool is far from stressed and there is no structural barrier to further shorting.

Options positioning has shifted materially toward calls. The put/call ratio has fallen to 0.48, more than one standard deviation below its 20-day average of 0.59, placing it toward the lower end of its recent range. That divergence between growing short interest and relatively light put demand suggests two distinct investor types are driving activity: equity-level short sellers pressing the recent price weakness, while options participants are not rushing to buy downside protection at current levels.

The bull case rests on relacorilant's commercial momentum. Lifyorli generated $47.6M in its first US quarter, the CHMP issued a positive opinion for the European market in 2026, and analysts who cover the name set targets between $161 and $165 after the Q2 print last July, when the stock jumped 25.6% in a single session. The bear case centres on the Most Favored Nation pricing policy, which complicates any non-US launch and has caused at least one firm, Wolfe Research, to move to Underperform with a $50 target. That target sits well below both the current price and the consensus, and the gap between $50 and $165 reflects genuine disagreement about how much of the international opportunity is accessible under current pricing dynamics.

Insider sales over the past 90 days have totalled roughly $17.5M on a net basis, though every disclosed transaction is flagged as being executed under a pre-arranged 10b5-1 plan, which limits how much conviction can be read into the timing. BlackRock added 3.4M shares in the most recent quarter, bringing its position to 8.9% of shares, while Ingalls and Snyder trimmed its 13G stake from 7.8% to 6.8% as of April. Those moves carry the standard caveat: 13D/G disclosures are event-driven around the 5% threshold, and positions may have changed since filing. Medicaid reimbursement data from CMS shows dollars reimbursed down 12% year-on-year in Q1 2026, a signal worth watching in the context of a commercial launch, though no measured lead to the company's reported financials has been established for any of its alt data series.

The print will test whether Lifyorli's commercial trajectory and the relacorilant resubmission timeline can hold the valuation case together after a month in which the stock gave back nearly a third of its value.